www.fdanews.com/articles/202217-niramais-breast-cancer-screening-test-earns-ce-mark
Niramai’s Breast Cancer Screening Test Earns CE Mark
April 7, 2021
Niramai has received CE mark certification for Thermalytix, a breast cancer testing solution that uses thermal sensing and artificial intelligence.
The test uses a high-resolution thermal sensing device and a cloud-based analytics system to analyze thermal images for early breast cancer screening.
According to the company, its trials so far have shown that the test is 27 percent more accurate than mammography and demonstrated a 70 percent higher positive predictive value than thermography. The test can detect cancer lesions as small as 4 millimeters with no palpable lumps, Niramai said.